Moreover, decreased expression of TFPI-2 associated with hypermethylation of the gene promoter was found in eight out of 10 patients with advanced stage of cancer (III or IV) compared to only one out of seven with stage I or II NSCLC (P=0.02). The gene discussed is TFPI2; the disease is cancer.